At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 1,328 enrolled
Drug / intervention
Spiriva HandiHalerdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MATHS: Assessment of Health-status of Patients With COPD on MAintenance THerapy With Spiriva® HH Measured by CAT Test
In Brief
A Phase 4 clinical trial evaluating Spiriva HandiHaler for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 1,328 participants across 247 sites.
Detailed Summary
To evaluate the early (3-month) impact of the long-acting anticholinergic Spiriva HH maintenance treatment on the COPD symptoms using the novel COPD Assessment test (CAT) in the real life setting of COPD patients, previously treated with short-acting bronchodilator on regular or as-needed basis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesPoland
CollaboratorsPfizer
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2011
First PostedJul 2012
Primary CompletionMar 2013
TodayJul 2026
First PostedJul 19, 2012
Enrollment StartNov 1, 2011
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 14.0 years ago
Interventions
Spiriva HandiHalerdrug